|
KMID : 0043320210440030293
|
|
Archives of Pharmacal Research
2021 Volume.44 No. 3 p.293 ~ p.309
|
|
|
Treatments of inflammatory bowel disease toward personalized medicine
|
|
Kim Ki-Uk
Kim Ji-Su
Kim Wan-Hoon
Min Hye-Young
Choi Chang-Hwan
|
|
|
Abstract
|
|
|
|
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic inflammatory disease characterized by intestinal inflammation and epithelial injury. For the treatment of IBD, 5-aminosalicylic acids, corticosteroids, immunomodulators, and biologic agents targeting tumor necrosis factor (TNF)-α, α4β7-integrin, and interleukin (IL)-12/23 have been widely used. Especially, anti-TNF-α antibodies are the first biologic agents that presently remain at the forefront. However, 10?30% of patients resist biologic agents, including anti-TNF-α agents (primary non-responder; PNR), and 20?50% of primary responders develop treatment resistance within one year (secondary loss of response; SLR). Nonetheless, the etiologies of PNR and SLR are not clearly understood, and predictors of response to biologic agents are also not defined yet. Numerous studies are being performed to discover prediction markers of the response to biologic agents, and this review will introduce currently available therapeutic options for IBD, biologics under investigation, and recent studies exploring various predictive factors related to PNR and SLR.
|
|
|
KEYWORD
|
|
|
Inflammatory bowel disease, Ulcerative colitis, Crohn’s disease, Personalized medicine, Biologic agent
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|